Irradiation Enhances the Tumor Tropism and Therapeutic Potential of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Secreting Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Glioma Therapy
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Irradiation is a standard therapy for gliomas and many other cancers. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is one of the most promising candidates for cancer gene therapy. Here, we show that tumor irradiation enhances the tumor tropism of human umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) and the therapeutic effect of TRAIL delivered by UCB-MSCs. The sequential treatment with irradiation followed by TRAIL-secreting UCB-MSCs (MSC-TRAIL) synergistically enhanced apoptosis in either TRAIL-sensitive or TRAIL-resistant glioma cells by upregulating the death receptor 5 and by inducing caspase activation. Migration assays showed greater MSC migration toward irradiated glioma cells and the tumor site in glioma-bearing mice compared with unirradiated tumors. Irradiated glioma cells had increased expression of interleukin-8 (IL-8), which leads to the upregulation of the IL-8 receptor on MSCs. This upregulation, which is involved in the migratory capacity of UCB-MSCs, was confirmed by siRNA inhibition and an antibody-neutralizing assay. In vivo survival experiments in orthotopic xenografted mice showed that MSC-based TRAIL gene delivery to irradiated tumors had greater therapeutic efficacy than a single treatment. These results suggest that clinically relevant tumor irradiation increases the therapeutic efficacy of MSC-TRAIL by increasing tropism of MSCs and TRAIL-induced apoptosis, which may be a more useful strategy for cancer gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0342 · Cited by 3,370
Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model
Nakamura, K., Ito, Y., Kawano, Y., Kurozumi, K., Kobune, M., Tsuda, H., Bizen, A., Honmou, O., Niitsu, Y., & Hamada, H. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302276 · Cited by 597
Rebelatto, C. K., Aguiar, A. M., Moretão, M. P., Senegaglia, A. C., Hansen, P., Barchiki, F., Oliveira, J., Martins, J., Kuligovski, C., Mansur, F., et al. (2008) · Experimental Biology and Medicine · doi:10.3181/0712-rm-356 · Cited by 429
Research works printed but not linked: 41
- Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, 987, 10.1056/NEJMoa043330 · DOI · Paper page
- McGirt, 2009, Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme, J Neurosurg, 110, 583, 10.3171/2008.5.17557 · DOI · Paper page
- Louis, 2007, The 2007 WHO classification of tumours of the central nervous system, Acta Neuropathol, 114, 97, 10.1007/s00401-007-0243-4 · DOI · Paper page
- Donaldson, 2006, Advances toward an understanding of brainstem gliomas, J Clin Oncol, 24, 1266, 10.1200/JCO.2005.04.6599 · DOI · Paper page
- Pittenger, 1999, Multilineage potential of adult human mesenchymal stem cells, Science, 284, 143, 10.1126/science.284.5411.143 · DOI · Paper page
- Wagner, 2005, Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood, Exp Hematol, 33, 1402, 10.1016/j.exphem.2005.07.003 · DOI · Paper page
- Lawler, 2006, Genetic strategies for brain tumor therapy, Cancer Gene Ther, 13, 225, 10.1038/sj.cgt.7700886 · DOI
- Hamada, 2005, Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy, Cancer Sci, 96, 149, 10.1111/j.1349-7006.2005.00032.x · DOI · Paper page
- Hong, 2009, Antitumor treatment using interleukin- 12-secreting marrow stromal cells in an invasive glioma model, Neurosurgery, 64, 1139, 10.1227/01.NEU.0000345646.85472.EA · DOI
- Nakamizo, 2005, Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas, Cancer Res, 65, 3307, 10.1158/0008-5472.CAN-04-1874 · DOI · Paper page
- Miletic, 2007, Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene, Mol Ther, 15, 1373, 10.1038/sj.mt.6300155 · DOI · Paper page
- Kim, 2008, Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma, Cancer Res, 68, 9614, 10.1158/0008-5472.CAN-08-0451 · DOI · Paper page
- Sasportas, 2009, Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy, Proc Natl Acad Sci USA, 106, 4822, 10.1073/pnas.0806647106 · DOI · Paper page
- Menon, 2009, Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy, Stem Cells, 27, 2320, 10.1002/stem.136 · DOI · Paper page
- Jeong, 2005, Differential gene expression profiling of human umbilical cord blood-derived mesenchymal stem cells by DNA microarray, Stem Cells, 23, 584, 10.1634/stemcells.2004-0304 · DOI · Paper page
- Uccelli, 2007, Mesenchymal stem cells: A new strategy for immunosuppression?, Trends Immunol, 28, 219, 10.1016/j.it.2007.03.001 · DOI · Paper page
- Sato, 2005, Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors, Cancer Gene Ther, 12, 757, 10.1038/sj.cgt.7700827 · DOI
- Klopp, 2007, Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment, Cancer Res, 67, 11687, 10.1158/0008-5472.CAN-07-1406 · DOI · Paper page
- Zielske, 2009, Radiation increases invasion of gene-modified mesenchymal stem cells into tumors, Int J Radiat Oncol Biol Phys, 75, 843, 10.1016/j.ijrobp.2008.06.1953 · DOI
- Pollack, 2001, Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells, Clin Cancer Res, 7, 1362
- Dyer, 2007, Barriers to effective TRAIL-targeted therapy of malignancy, J Clin Oncol, 25, 4505, 10.1200/JCO.2007.13.1011 · doi:10.1200/jco.2007.13.1011
- Mahalingam, 2009, TRAIL receptor signaling and modulation: Are we on the right TRAIL?, Cancer Treat Rev, 35, 280, 10.1016/j.ctrv.2008.11.006 · DOI · Paper page
- Nagane, 2007, Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand, J Neurosurg, 106, 407, 10.3171/jns.2007.106.3.407 · DOI
- Fiveash, 2008, Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5, Int J Radiat Oncol Biol Phys, 71, 507, 10.1016/j.ijrobp.2008.02.005 · DOI
- Yang, 2004, Mesenchymal stem/progenitor cells developed in cultures from UC blood, Cytotherapy, 6, 476, 10.1080/14653240410005041 · DOI · Paper page
- Kim, 2006, Cancer gene therapy using a novel secretable trimeric TRAIL, Gene Ther, 13, 330, 10.1038/sj.gt.3302658 · DOI
- Kim, 2009, Overexpression of CXC chemokine receptors is required for the superior glioma-tracking property of umbilical cord blood-derived mesenchymal stem cells, Stem Cells Dev, 18, 511, 10.1089/scd.2008.0050 · DOI · Paper page
- Ringe, 2007, Towards in situ tissue repair: Human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 And CCR2, and migrate upon stimulation with CXCL8 but not CCL2, J Cell Biochem, 101, 135, 10.1002/jcb.21172 · DOI · Paper page
- Birnbaum, 2007, Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines, J Neurooncol, 83, 241, 10.1007/s11060-007-9332-4 · DOI · Paper page
- Ries, 2007, MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: Differential regulation by inflammatory cytokines, Blood, 109, 4055, 10.1182/blood-2006-10-051060 · DOI · Paper page
- Friedman, 2002, Immune modulation by ionizing radiation and its implications for cancer immunotherapy, Curr Pharm Des, 8, 1765, 10.2174/1381612023394089 · DOI · Paper page
- Li, 2007, The role of PDGF in radiation oncology, Radiat Oncol, 2, 5, 10.1186/1748-717X-2-5 · DOI
- Shah, 2003, Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo, Oncogene, 22, 6865, 10.1038/sj.onc.1206748 · DOI
- Lee, 2002, Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector, Neoplasia, 4, 312, 10.1038/sj.neo.7900245 · DOI
- Griffith, 2000, Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis, J Immunol, 165, 2886, 10.4049/jimmunol.165.5.2886 · DOI · Paper page
- Ashkenazi, 2008, Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL), J Clin Oncol, 26, 3621, 10.1200/JCO.2007.15.7198 · DOI · Paper page
- Shankar, 2004, Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms, The Prostate, 61, 35, 10.1002/pros.20069 · DOI
- Gong, 2000, Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells, Cancer Res, 60, 5754
- Marini, 2005, Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis, BMC Cancer, 5, 5, 10.1186/1471-2407-5-5 · DOI
- Kosztowski, 2009, Applications of neural and mesenchymal stem cells in the treatment of gliomas, Expert Rev Anticancer Ther, 9, 597, 10.1586/era.09.22 · DOI
- Chen, 2006, The sensitivity of human mesenchymal stem cells to ionizing radiation, Int J Radiat Oncol Biol Phys, 66, 244, 10.1016/j.ijrobp.2006.03.062 · DOI · Paper page
Cited by
Meng, W., He, C., Hao, Y., Wang, L., Li, L., & Zhu, G. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1748758 · Cited by 592
Mesenchymal stem cells engineered for cancer therapy
Shah, K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.010 · Cited by 322
TRAIL on trial: preclinical advances in cancer therapy
Stuckey, D. W., & Shah, K. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.08.007 · Cited by 276
Zhuang, W.-Z., Lin, Y.-H., Su, L.-J., Wu, M.-S., Jeng, H.-Y., Chang, H.-C., Huang, Y.-H., & Ling, T.-Y. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00725-7 · Cited by 258
Klopp, A. H., Zhang, Y., Solley, T., Amaya-Manzanares, F., Marini, F., Andreeff, M., Debeb, B., Woodward, W., Schmandt, R., Broaddus, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1916 · Cited by 178
Mesenchymal stem cell secretome and regenerative therapy after cancer
Zimmerlin, L., Park, T. S., Zambidis, E. T., Donnenberg, V. S., & Donnenberg, A. D. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.010 · Cited by 168
Xu, S., Menu, E., Becker, A. D., Van Camp, B., Vanderkerken, K., & Van Riet, I. (2012) · Stem Cells · doi:10.1002/stem.787 · Cited by 103
Metadata
- Authors
- Kim, S. M., Oh, J. H., Park, S. A., Ryu, C. H., Lim, J. Y., Kim, D.-S., Chang, J. W., Oh, W., & Jeun, S.-S.
- Venue
- Stem Cells
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-12-01
- Volume
- 28
- Issue
- 12
- Pages
- 2217-2228
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W1984423771
- Cited by
- 136
- References
- 3
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.